GSK.L - GlaxoSmithKline plc

LSE - LSE Delayed Price. Currency in GBp
-1.40 (-0.08%)
At close: 4:35PM GMT
Stock chart is not supported by your current browser
Previous Close1,701.20
Bid1,698.40 x 0
Ask1,698.60 x 0
Day's Range1,677.79 - 1,710.40
52 Week Range1,408.80 - 1,796.40
Avg. Volume8,377,118
Market Cap85.213B
Beta (3Y Monthly)0.41
PE Ratio (TTM)18.62
EPS (TTM)91.30
Earnings DateFeb 5, 2020
Forward Dividend & Yield0.76 (4.37%)
Ex-Dividend Date2019-11-14
1y Target Est1,644.50
  • Reuters

    UPDATE 1-GSK sees breakthrough in shingles vaccine output in 2024

    GlaxoSmithKline said further growth from its shingles vaccine, which has boosted earnings, would be reined in by limited capacity until 2024, but a new bioreactor facility would then be ready to bring a step change in production. GSK, Britain's largest drugmaker, had originally envisaged a gradual launch in the United States, its biggest market, but regulators unexpectedly recommended Shingrix not only for people reaching the age of 50 but also to replace an established product. A bioreactor complex in Belgium that makes so-called antigens - proteins that trigger an immune reaction against the shingles virus - is reaching its capacity limits.

  • Pfizer Stock Is A Top Pharma Company — But Should You Buy It?
    Investor's Business Daily

    Pfizer Stock Is A Top Pharma Company — But Should You Buy It?

    Pfizer stock has tumbled, below other pharmaceutical stocks. Recent news has been upbeat with a drug approval and acquisitions. But the question remains: Is Pfizer stock a buy right now?

  • Reuters

    AstraZeneca succeeds in treating lupus in late-stage study

    AstraZeneca Plc said on Monday its experimental treatment significantly reduced disease activity in patients with autoimmune disorder lupus, in a late-stage study. The results pit the British drugmaker's anifrolumab against rival GlaxoSmithKline Plc's Benlysta - the only new drug approved for lupus in the last 60 years. Benlysta recorded 473 million pounds of global sales in 2018, up 26% from a year earlier.

  • Need To Know: GlaxoSmithKline plc (LON:GSK) Insiders Have Been Selling Shares
    Simply Wall St.

    Need To Know: GlaxoSmithKline plc (LON:GSK) Insiders Have Been Selling Shares

    We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly...

  • Thomson Reuters StreetEvents

    Edited Transcript of GSK.L earnings conference call or presentation 30-Oct-19 2:00pm GMT

    Q3 2019 GlaxoSmithKline PLC Earnings Call

  • GSK raises profit forecast after shingles vaccine sales boost

    GSK raises profit forecast after shingles vaccine sales boost

    The British drugmaker's shares rose as much as 3% to a more than a six-year high after the company said it now expected profit to be roughly flat at constant currency for the year, compared with a previous forecast of a fall of 3% to 5%. CEO Emma Walmsley has embarked on a plan to rejuvenate GSK, which has included the spin off or sale of a number of businesses since she took over in 2017. GSK's leaner structure has also helped the company focus more on its pharmaceuticals business and build a newer pool of treatments, including its shingles vaccine, Shingrix.

  • Reuters

    UPDATE 2-GSK raises profit forecast after shingles vaccine sales boost

    GlaxoSmithKline on Wednesday raised its annual profit forecast for the second time this year as sales of its shingles vaccine beat expectations and older medicines, including HIV treatments, continued to sell well. The British drugmaker's shares rose as much as 3% to a more than a six-year high after the company said it now expected profit to be roughly flat at constant currency for the year, compared with a previous forecast of a fall of 3% to 5%. CEO Emma Walmsley has embarked on a plan to rejuvenate GSK, which has included the spin off or sale of a number of businesses since she took over in 2017.

  • T Rowe Price Trims Microsoft, Exits Merck

    T Rowe Price Trims Microsoft, Exits Merck

    Fund's largest sales of the 3rd quarter Continue reading...

  • 5 Undervalued Stocks to Buy

    5 Undervalued Stocks to Buy

    [Editor's note: "5 Undervalued Stocks to Buy" was previously published in September 2019. It has since been updated to include the most relevant information available.]Overall, the stock market continued its improvement throughout 2019, compared to where it ended in 2018; it has been a complete turnaround from last year's drop when stocks entered bear-market territory.But even though many stocks have completely erased all of their losses and made it back into the green, not all stocks have done so well. What this means is that while there are still plenty of duds out there, there are also a few undervalued stocks to buy; it has just become a little trickier to find them amid all the flashy comeback stories.InvestorPlace - Stock Market News, Stock Advice & Trading TipsTo find the best stocks to buy now, disciplined investors might start with their own watch list, which should contain "wish list" stocks that are usually too expensive or have been put there to be on the back burner for later.Among such stocks, companies that got left out of the rally are the most compelling. Even better, some of the best undervalued stocks to buy are those that dropped by double-digit percentages during the current rally. * 7 Top-Notch REITs to Buy for Income Why is that?Stocks that have already priced in current and possible negative news typically lower the risk for investors. Such companies may work to resolve the business problem at hand, which improves its prospects and leads to a higher share price in the long run. As long as the bad news reported is a temporary setback and the business model is not broken, the risks behind buying a stock on a dip are lower.With all of that in mind, here are five undervalued stocks to buy that aren't as scary as they seem. Sony (SNE)Investors who held Sony (NYSE:SNE) stock through the Q2 2019 earnings report posted on July 30 enjoyed the rally that followed. The stock rose from $54.50 to nearly $60 recently and has been trading in the $58-$59 range ever since.The company reported revenue falling just 1.4% year-over-year but operating income rose 18%, up 35.9 billion yen (US $332.2 million), but the Q3 report doesn't look as bright.Now that Sony is trading at yearly highs, investors need not sell the stock just yet.When Sony's Playstation 5 arrives, SNE will have more power than ever. Though the PS5 release will release no sooner than mid-2020, 8K support and game refreshes should give Sony another boost in revenue when the time comes.Sony faced a few headwinds in the quarter. Contributions from first-party software titles fell. Sales of non-first party titles declined. But PS4 hardware sales rose, as did network service sales, including sales of PlayStation Plus. Celestica (CLS)In July, Celestica (NYSE:CLS) reported respectable Q3/2019 results recently, but it didn't move the CLS stock out of its $6 trading range.The company supplies equipment in ATS aerospace and defense, industrial, smart energy, health tech and capital equipment. Its enterprise unit consists of servers and storage. Why then, should investors believe the company will offset the weakness it faces in the eroding semiconductor market?Celestica is cutting costs in operations to align the business with the lower revenue. It will continue to build its capital equipment business. Management believes the fundamentals in this space will only improve in the long run. As next-generation adoption in display continues, its OLED business, for example, will add to its bottom line. * 7 Stocks to Buy With 100% Upside Potential Celestica stock is still an undervalued play worth considering. The stock may underperform a while longer and risks disappointing investors. AbbVie (ABBV)Source: Shutterstock Back when I first wrote this list of undervalued stocks, Allergan (NYSE:AGN) was the pick in this slot. And it paid off. Investors buying Allergan at the start of 2019 may have made up to $50 a share, peak to trough.In June, the stock fell below $115, only to peak at around $165 in July when my new pick, AbbVie (NYSE:ABBV), agreed to buy out the firm for $63 billion. AbbVie's rationale for acquiring Allergan is two-fold.First, it views Allergan's portfolio of products, including Botox, as attractive. Second, it has the time to use the strong cash flow from Humana to pay off its Allergan acquisition. Once Humana faces fierce competition from generics, AbbVie will have paid off much of the debt related to the AGN buyout. And in a few year's time, Allergan's drugs in the development pipeline will be ready for market.AbbVie's long-term future planning through the AGN acquisition makes AbbVie stock appealing for dividend-income investors. Even though shares rose from a $62.66 52-week low to $71.55, the stock still pays a dividend that yields 6%.At a Sep. 10 Healthcare Conference, AbbVie reiterated its commitment to cut debt and to continue growing its dividend. It will also allocate some cash for smaller mid- to late-state pipeline opportunities. Management has a good handle on integrating Allergan into its business but it will not let its existing pipeline suffer in any way.ABBV trades at an ~10% discount to the analyst price target of $79, but I think the AGN acquisition brings ABBV far more upside than that. Innoviva (INVA)Source: Shutterstock Innoviva (NASDAQ:INVA) is another stock in the drug space whose large drop starting in late January continued throughout 2019. The stock may not yet be done falling. Why not?The fall began when the FDA approved Mylan's (NASDAQ:MYL) generic version of Advair, which GlaxoSmithKline (NYSE:GSK) produces. This forced investors to worry about Innoviva's prospects because the company is paid royalties from Glaxo. In the third quarter, Innova received $65.1 million in royalty revenues from Glaxo.Investors appear to be overreacting to the generic competition. If demand for Innoviva's formulation does not drop and prices hold, royalty revenues should not fall as much as markets think, which makes INVA an ideal undervalued stock to buy now.Innoviva shares trended lower throughout 2019, as the stock lost $3 on its stock price by late-July. Investors sold the stock following the company's weak Q2 report. Innoviva reported Glaxo (NYSE:GSK) royalties falling 18% to $313.9 million. Overall, there was a net income decline of 31% (an EPS of $0.34).In its press release, the company said:"Management and the board continue to examine potential strategic actions to maximize future shareholder value." * 7 Safe Stocks to Buy and Hold Through 2020 Innoviva incurred expenses related to the evaluation of strategic options. But it will need to deliver on better shareholder value to attract stock buyers. Vodafone (VOD)Source: Apple Telecom stocks were out of favor heading into 2019. Now, telecom stocks are no longer out of favor. But Vodafone (NASDAQ:VOD), which after cratering in May, has just barely climbed back to its pre-Christmas levels. So VOD is definitely still an undervalued stock.On July 26, Vodafone reported revenue stabilizing, falling just 2.3% Y/Y (its next report was expected toward the end of October). The results sent VOD stock up 9% on the day. And ever since the stock bottomed at $16, it continues to run higher, closing recently at close to $20.In the fiscal Q1 2020 report, Vodafone said it enjoyed record low mobile contract churn. The deepening customer engagement will only strengthen as the telecom company launches 5G in all major EU markets.Service revenue in Q1 was mostly flat, down 0.2% and 0.5 pp sequentially.Simplifying the mobile plan offering will likely lead to higher revenue growth ahead. For example, Vodafone migrated 500,000 SIMs to a new unlimited offer. This will also increase ARPU and keep customers from switching to competitor services.Vodafone shares pay a dividend yield of 4.95%. If Vodafone grows its UK business as it signs on users to its 5G services and cuts costs as it signs on more customers, VOD stock will finally move higher.As of this writing, Chris Lau owned shares of Innoviva and AbbVie. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Cybersecurity Stocks to Keep Your Portfolio Safe * 7 Top-Notch REITs to Buy for Income * 5 Reasons Why I Still Believe in Hexo Stock The post 5 Undervalued Stocks to Buy appeared first on InvestorPlace.

  • Reuters

    UPDATE 2-FDA investigating whether Zantac causes carcinogens to form in users

    The U.S. Food and Drug Administration is investigating whether the popular heartburn drug Zantac causes carcinogens to form in the bodies of users, in an effort to fully understand the risks posed by the already recalled drug, the agency's spokesman said on Thursday. The issue of whether ranitidine, commonly known as Zantac, causes levels of the probable carcinogen N-nitrosodimethylamine (NDMA) to rise in users' bodies has been raised previously by Valisure, an online pharmacy that originally flagged the potential contamination of ranitidine to the FDA. Zantac, sold over-the-counter in the United States by French drugmaker Sanofi SA, and some of its generic versions, have been recalled due to possible NDMA contamination of pills that had not yet been consumed.

  • Benzinga

    The Daily Biotech Pulse: Acorda To Trim Jobs, GlaxoSmithKline Gets FDA Nod, Edward Lifesciences Posts Q3 Beat-And-Raise

    The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Oct. 23.) Applied Therapeutics Inc (NASDAQ: APLT ) AVITA ...

  • Is GlaxoSmithKline plc's (LON:GSK) 4.8% Dividend Worth Your Time?
    Simply Wall St.

    Is GlaxoSmithKline plc's (LON:GSK) 4.8% Dividend Worth Your Time?

    Today we'll take a closer look at GlaxoSmithKline plc (LON:GSK) from a dividend investor's perspective. Owning a...

  • Reuters

    UPDATE 1-GSK gets FDA nod for wider use of ovarian cancer drug Zejula

    GlaxoSmithKline said U.S. regulators had approved its ovarian cancer treatment Zejula for wider use in some advanced cancers, in a boost to the British drugmaker's oncology portfolio as it competes with rival AstraZeneca. The U.S. Food and Drug Administration approval is for the drug's use in advanced ovarian, fallopian tube, or primary peritoneal cancer patients who have undergone at least three prior chemotherapy regimens and whose disease has come back. Zejula is currently approved as a maintenance therapy for adults with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer and whose tumours have completely or partially responded to platinum-based chemotherapy treatments.

  • Business Wire

    GSK Announces U.S. Food and Drug Administration Approval of Additional Indication for Zejula (niraparib) for Late-line Treatment for Women with Recurrent Ovarian Cancer

    PHILADELPHIA-- -- Expanded indication allows for treatment of women whose advanced ovarian cancer is associated with homologous recombination deficiency Zejula is now the only, once-daily PARP inhibitor approved as monotherapy treatment for recurrent ovarian cancer beyond those with a BRCA mutation in both the recurrent maintenance and late-line treatment settings GlaxoSmithKline today announced that ...

  • GSK sells two vaccines in deal valued at up to $1.1 billion
    American City Business Journals

    GSK sells two vaccines in deal valued at up to $1.1 billion

    GSK has its U.S. corporate headquarters at Philadelphia’s Navy Yard, where the company has more than 1,000 people.

  • Reuters

    TIMELINE-Popular heartburn medicine Zantac pulled off store shelves

    The U.S. Food and Drug Administration and international health authorities are investigating the safety of Zantac heartburn medicine, also sold generically as ranitidine, after finding a probable cancer-causing impurity in the drug. Ranitidine is the newest drug in which presence of cancer causing impurities have been found. Glaxo Holdings Ltd, now a part of GlaxoSmithKline PLC , receives its first U.S. FDA approval for Zantac as a short-term treatment of a common form of ulcers.

  • Reuters

    Teva's UK arm recalls some batches of Ranitidine - Medicines watchdog

    Teva Pharmaceutical's UK unit has recalled some batches of heartburn medicine Ranitidine, Britain's medicines watchdog said on Thursday, making it the latest drugmaker to pull the product. Teva, the world's largest generic drugmaker, is recalling all unexpired stock of Ranitidine Effervescent Tablets in 150 micrograms and 300 micrograms dosages, the Medicines and Healthcare products Regulatory Agency (MHRA) said Teva did not immediately respond to a request for comment.

  • Here’s just how big the performance gap is for British companies exposed to Brexit

    Here’s just how big the performance gap is for British companies exposed to Brexit

    The performance of British firms who rely on the majority of their sales from European markets have plunged since the country voted to leave the EU in 2016, according to new data.

  • MarketWatch

    Pound surges on report of possible draft Brexit deal

    The British pound jumped Tuesday, shaking off losses seen at the start of the week, after upbeat comments over a possible Brexit deal from the European Union’s negotiator.


    Ariel's Rhupal Bhansali's Philosophy of Non-Consensus Investing

    A summary of Bhansali's investment philosophy and four stock picks Continue reading...

  • Hedge Funds Sold GlaxoSmithKline plc (GSK) A Little Bit Too Early
    Insider Monkey

    Hedge Funds Sold GlaxoSmithKline plc (GSK) A Little Bit Too Early

    Russell 2000 ETF (IWM) lagged the larger S&P 500 ETF (SPY) by more than 10 percentage points since the end of the third quarter of 2018 as investors first worried over the possible ramifications of rising interest rates and the escalation of the trade war with China. The hedge funds and institutional investors we track […]

  • Hedge Funds Have Never Been More Bullish On Danaher Corporation (DHR)
    Insider Monkey

    Hedge Funds Have Never Been More Bullish On Danaher Corporation (DHR)

    Investing in small cap stocks has historically been a way to outperform the market, as small cap companies typically grow faster on average than the blue chips. That outperformance comes with a price, however, as there are occasional periods of higher volatility. The last 12 months is one of those periods, as the Russell 2000 […]

  • Drugmakers in spotlight as GSK recalls Zantac
    Reuters Videos

    Drugmakers in spotlight as GSK recalls Zantac

    Popular heartburn medicine Zantac may be rather less popular after a move by its makers to recall it. The decision, says GlaxoSmithKline, a 'precaution' ... After the U.S. FDA found "unacceptable" levels of probable cancer-causing impurity in the drug. It's not the first such move for what is also sold generically as ranitidine. Swiss drugmaker Novartis halted global distribution last month. Last week, Walmart and CVS Health, Walgreens Boots Alliance and Rite Aid suspended over-the-counter sales. Canada has asked drugmakers to halt distribution - Ireland and Hong Kong have pulled products. UK regulators said GSK was recalling four prescription-only Zantac medicines. An over-the-counter version made by a different company is not affected. Also in the sector spotlight: Johnson & Johnson. The drugs and consumer goods giant ordered to pay eight billion dollars in punitive damages ... To a plaintiff in the US, a Philadelphia jury has said. The damages dwarf an initial 680,000 dollar award ... Which concerns claims J&J failed to warn that young men using its antipsychotic drug Risperdal could grow breasts. Thousands of Risperdal cases are pending in the state.